{"prompt": "['hemodynamic support))', 'Myositis/Polymyositis (\"Poly/myositis\")', 'Any Grade', 'General Guidance', 'For Any Grade:', '-', 'Monitor patients for signs and symptoms of poly/myositis. Typically,', 'muscle weakness/pain occurs in proximal muscles including upper', 'arms, thighs, shoulders, hips, neck and back, but rarely affects the', 'extremities including hands and fingers; also difficulty breathing and/or', 'trouble swallowing can occur and progress rapidly. Increased general', 'feelings of tiredness and fatigue may occur, and there can be new-onset', 'falling, difficulty getting up from a fall, and trouble climbing stairs,', 'standing up from a seated position, and/or reaching up.', 'If poly/myositis is suspected, a Neurology consultation should be', 'obtained early, with prompt guidance on diagnostic procedures.', 'Myocarditis may co-occur with poly/myositis; refer to guidance under', 'Myocarditis. Given breathing complications, refer to guidance under', 'Pneumonitis/ILD.', 'Given possibility of an existent (but previously unknown) autoimmune', 'disorder, consider Rheumatology consultation.', '-', 'Consider, as necessary, discussing with the study physician.', 'Initial work-up should include clinical evaluation, creatine kinase,', 'aldolase, LDH, BUN/creatinine, erythrocyte sedimentation rate or C-', 'reactive protein level, urine myoglobin, and additional laboratory work-', 'up as indicated, including a number of possible', 'rheumatological/antibody tests (i.e., consider whether a rheumatologist', 'consultation is indicated and could guide need for rheumatoid factor,', 'antinuclear antibody, anti-smooth muscle, antisynthetase [such as anti-', 'Jo-1], and/or signal-recognition particle antibodies). Confirmatory', 'testing may include electromyography, nerve conduction studies, MRI', 'of the muscles, and/or a muscle biopsy. Consider Barium swallow for', 'evaluation of dysphagia or dysphonia.', 'Patients should be thoroughly evaluated to rule out any alternative etiology (e.g.,', 'disease progression, other medications, or infections).', 'Grade 1', '-', 'No dose modifications.', 'For Grade 1:', '-', '(mild pain)', 'Monitor and closely follow up in 2 to 4 days for clinical symptoms and', 'initiate evaluation as clinically indicated.', '-', 'Consider Neurology consult.', '-', 'Consider, as necessary, discussing with the study physician.', 'Grade 2', 'Hold study drug/study regimen dose until', 'For Grade 2:', '(moderate', 'pain', 'resolution to Grade 1.', '-', 'Monitor symptoms daily and consider hospitalization.', 'associated', 'with', '-', '- Permanently discontinue study', 'Obtain Neurology consult, and initiate evaluation.', 'weakness; pain limiting', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 107 de 123']['instrumental activities', '-', 'drug/study regimen if it does not', 'Consider, as necessary, discussing with the study physician.', 'of daily living [ADLs])', '-', 'resolve to Grade 1 within 30 days or', 'If clinical course is rapidly progressive (particularly if difficulty', 'breathing and/or trouble swallowing), promptly start IV', 'if there are signs of respiratory', 'methylprednisolone 2 to 4 mg/kg/day systemic steroids along with', 'insufficiency.', 'receiving input from Neurology consultant', '-', 'If clinical course is not rapidly progressive, start systemic steroids (e.g.,', 'prednisone 1 to 2 mg/kg/day PO or IV equivalent); if no improvement', 'within 3 to 5 days, continue additional work up and start treatment with', 'IV methylprednisolone 2 to 4 mg/kg/day', '-', 'If after start of IV methylprednisolone at 2 to 4 mg/kg/day there is no', 'improvement within 3 to 5 days, consider start of immunosuppressive', 'therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2', 'weeks). Caution: It is important to rule out sepsis and refer to infliximab', 'label for general guidance before using infliximab.', '-', 'Once the patient is improving, gradually taper steroids over >28 days', 'and consider prophylactic antibiotics, antifungals, or anti-PJP treatment', '(refer to current NCCN guidelines for treatment of cancer-related', 'infections [Category 2B recommendation].', 'Grade 3 or 4', 'For Grade 3:', 'For Grade 3 or 4 (severe or life-threatening events):', '(pain associated with', '-', 'Hold study drug/study regimen dose until', 'Monitor symptoms closely; recommend hospitalization.', 'severe', 'weakness;', '-', 'limiting', 'self-care', 'resolution to Grade 1.', 'Obtain Neurology consult, and complete full evaluation.', '-', 'ADLs)', 'Consider, as necessary, discussing with the study physician.', 'Permanently discontinue study drug/study', '-', 'Promptly start IV methylprednisolone 2 to 4 mg/kg/day systemic', 'regimen if Grade 3 imAE does not resolve', 'steroids along with receiving input from Neurology consultant.', 'to Grade 1 within 30 days or if there are', '-', 'If after start of IV methylprednisolone at 2 to 4 mg/kg/day there is no', 'signs of respiratory insufficiency.', 'improvement within 3 to 5 days, consider start of immunosuppressive', 'therapy such as TNF inhibitors (e.g., infliximab at 5 mg/kg every 2', 'weeks). Caution: It is important to rule out sepsis and refer to infliximab', 'label for general guidance before using infliximab.', 'For Grade 4:', '-', 'Consider whether patient may require IV IG, plasmapheresis.', '- Permanently discontinue study', '-', 'Once the patient is improving, gradually taper steroids over >28 days', 'drug/study regimen.', 'and consider prophylactic antibiotics, antifungals, or anti-PJP treatment', '(refer to current NCCN guidelines for treatment of cancer-related', 'infections [Category 2B recommendation]). a', 'ASCO Educational Book 2015 \"Managing Immune Checkpoint Blocking Antibody Side Effects\" by Michael Postow MD.', \"'FFDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury - Premarketing Clinical Evaluation.\", 'AChE Acetylcholine esterase; ADL Activities of daily living; AE Adverse event; ALP Alkaline phosphatase test; ALT Alanine aminotransferase; AST Aspartate aminotransferase; BUN Blood urea nitrogen; CT Computed', 'tomography; CTCAE Common Terminology Criteria for Adverse Events; ILD Interstitial lung disease; imAE immune-mediated adverse event; IG Immunoglobulin; IV Intravenous; GI Gastrointestinal; LFT Liver', 'function tests; LLN Lower limit of normal; MRI Magnetic resonance imaging; NCI National Cancer Institute; NCCN National Comprehensive Cancer Network; PJP Pneumocystis jirovecii pneumonia (formerly known', 'as Pneumocystis carinii pneumonia); PO By mouth; T3 Triiodothyronine; T4 Thyroxine; TB Total bilirubin; TNF Tumor necrosis factor; TSH Thyroid-stimulating hormone; ULN Upper limit of normal.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 108 de 123']\n\n###\n\n", "completion": "END"}